Last reviewed · How we verify
Phage Therapy
At a glance
| Generic name | Phage Therapy |
|---|---|
| Also known as | Phage, Antibiotics, targeted phage therapy |
| Sponsor | Barbara Wells Trautner |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Hypokalaemia
- Anaemia
- Constipation
- Endocarditis
- Wheezing
- Non-cardiac chest pain
- Dizziness
- Arthritis Bacterial
- Thrombocytosis
- Cardiac Ventricular Thrombosis
- Mitral Valve Incompetence
- Cerumen Impaction
Key clinical trials
- MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia (PHASE1)
- Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia (PHASE1, PHASE2)
- A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial) (PHASE2)
- Standard Treatment Associated With Phage Therapy Versus Placebo for Diabetic Foot Ulcers Infected by S. Aureus (PHASE1, PHASE2)
- Bacteriophages in Addition to Antibiotics for the Treatment of Patients With Infective Endocarditis (PHASE3)
- Bacteriophage Therapy for Staphylococcus Lugdunensis Prosthetic Joint Infection (PHASE1, PHASE2)
- Bacteriophage for Chronic Multidrug-Resistant Mycobacterium Abscessus Subsp. Abscessus Pulmonary Infection (PHASE1)
- Bacteriophages for Adults With Cystic Fibrosis and Chronic Achromobacter Lung Infection (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phage Therapy CI brief — competitive landscape report
- Phage Therapy updates RSS · CI watch RSS
- Barbara Wells Trautner portfolio CI